Researcher

Jing Li

Sun Yat-sen University

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 12, 2026 · JOURNAL ARTICLE

Establishment and application of a multiplex qPCR panel for multi-host surveillance of tick-Borne pathogens.

Emerging Microbes & Infections

A rigorously validated multiplex diagnostic panel with strong analytical performance (96.5% sensitivity/specificity, AUC 0.979) applied to clinical and epidemiological surveillance, but representing a diagnostic tool validation and descriptive screening study rather than a clinical outcome trial.

PromisingXinting Meng Tick Borne Diseases Jie Liu

Reported

Number of pathogens detected25

Number of multiplex qPCR assays8

Sensitivity96.5%

AUG 17, 2026 · JOURNAL ARTICLE

Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi)

BMC Medicine

Phase Ib/II trial showing modest efficacy (46.7% 6-month PFS) with manageable toxicity in a treatment-refractory population, but limited by small sample size, low objective response rate, and single-arm design without comparator.

PromisingChuqiao Liang Jing Li Cheng Fang

Reported

Sample size29

6-month PFS rate46.7%

6-month PFS 95% CI24.4–66.2